Table 1.
Pooled prevalence (PP) of long-term consequences of asymptomatic SARS-CoV-2 infection.
| Consequences | Data Source | Patients n/N |
PP(%) | 95%CI(%) | p-Value | I2(%) | p-Heterogeneity |
|---|---|---|---|---|---|---|---|
| At least one symptom | 1, 2, 4, 5 | 76/543 | 17.13 | 7.55–26.71 | <0.05 | 85.40 | <0.05 |
| Loss of taste | 3, 4 | 8/97 | 15.09 | 5.46–24.73 | <0.05 | - | - |
| Loss of smell | 3, 4 | 15/97 | 14.14 | −1.32–29.61 | >0.05 | 81.00 | <0.05 |
| Fatigue | 1, 2, 3, 4, 5 | 35/596 | 9.33 | 3.07–15.60 | <0.05 | 87.00 | <0.05 |
| Cough | 2, 4, 5 | 3/144 | 6.82 | −0.63–14.27 | >0.05 | - | - |
| Dyspnoea | 4, 5 | 5/144 | 5.38 | 0.70–10.07 | <0.05 | 0.00 | >0.05 |
| Ocular symptoms | 4, 5 | 2/99 | 4.55 | −1.61–10.70 | >0.05 | - | - |
| Headache | 2, 4, 5 | 4/144 | 4.49 | 0.19–8.80 | <0.05 | 0.00 | >0.05 |
| Muscle or joint pains | 1, 4 | 12/443 | 3.11 | −0.32–6.35 | >0.05 | 28.00 | >0.05 |
| Psychiatric disorders | 1, 5 | 11/454 | 2.76 | 1.15–4.36 | <0.05 | - | - |
| Neurological symptoms | 4, 5 | 10/454 | 2.51 | 0.97–4.04 | <0.05 | - | - |
| Loss of taste/smell | 1, 2, 5 | 4/499 | 2.39 | −3.54–8.31 | >0.05 | 66.30 | >0.05 |
| Hair loss | 4, 5 | 1/99 | 1.82 | −1.71–5.35 | >0.05 | - | - |
| Gastrointestinal symptoms | 1, 5 | 7/454 | 1.75 | 0.47–3.04 | <0.05 | - | - |
| Cutaneous lesions | 4, 5 | 4/498 | 0.81 | −0.01–1.63 | >0.05 | 0.00 | >0.05 |
| Palpitations and cardiac disorders | 1, 4 | 2/443 | 0.28 | −0.21–0.76 | >0.05 | 0.00 | >0.05 |
| Chest pain | 4, 5 | 0/99 | - | - | - | - | - |